SpectronRx, founded in 2004 in Indiana, USA, is a company specializing in radiopharmaceutical development and manufacturing services (CDMO/RDMO). The firm has established expertise in isotope supply, antibody/nanobody/peptide labeling, logistics, and FDA approval processes.
Recently, SpectronRx has accelerated its growth with an investment of USD 85 million.
As a globally recognized leader in radiopharmaceutical development and production, SpectronRx reliably supplies high-purity Actinium-225 (Ac-225) isotopes for clinical and research applications, fully compliant with international quality standards.
For more information, you can visit the link www.spectronrx.com.